Loading clinical trials...
Loading clinical trials...
A Phase 3, Open-label, Efficacy-Assessor-Blinded Study, Comparing the Safety and Efficacy of Upadacitinib to Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
Conditions
Interventions
Upadacitinib
Dupilumab
Locations
148
United States
Applied Research Center Of Arkansas /ID# 268547
Little Rock, Arkansas, United States
Stanford University School of Medicine - Palo Alto /ID# 269622
Palo Alto, California, United States
Integrative Skin Science and Research /ID# 265108
Sacramento, California, United States
Clearlyderm Dermatology - West Boca /ID# 266323
Boca Raton, Florida, United States
Pediatric Skin Research /ID# 266308
Coral Gables, Florida, United States
Neoclinical Research - Hialeah /ID# 269694
Hialeah, Florida, United States
Start Date
August 19, 2024
Primary Completion Date
July 1, 2030
Completion Date
July 1, 2030
Last Updated
April 7, 2026
NCT07262983
NCT06389136
NCT06342713
NCT07290803
NCT07223697
NCT07265479
Lead Sponsor
AbbVie
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions